The purpose of this study is to look at combining the study drug IMGN632 with standard therapies (azacitidine and/or venetoclax) for acute myeloid leukemia (AML). The study will look at what effects (both good and/or bad) this combination has on the cancer, how well this combination works to treat cancer, and what a safe dose of the study drug is.

IMGN5632 is considered experimental, meaning it has not yet been approved by the U.S. Food and Drug Administration (FDA) or other health authorities.

Participants will receive IMGN5632 in combination with venetoclax andazacitidine.

The study will last approximately 1 year and 9 months (21 months). Participants can stay on the study as long as they are doing well. Each cycle is 28 days long and will consist of approximately 2 outpatient visits per month, after the first cycle.